ALLO Stock Summary and Trading Ideas (Allogene Therapeutics | NASDAQ:ALLO)

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Allogene Therapeutics trades on the NASDAQ stock market under the symbol ALLO.

As of August 13, 2026, ALLO stock price declined to $1.99 with 4,881,504 million shares trading.

ALLO has a beta of 1.47, meaning it tends to be more sensitive to market movements. ALLO has a correlation of 0.07 to the broad based SPY ETF.

ALLO has a market cap of $686.86 million. This is considered a Small Cap stock.

Last quarter Allogene Therapeutics reported $5 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.02.

In the last 3 years, ALLO traded as high as $5.78 and as low as $.86.

The top ETF exchange traded funds that ALLO belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWN.

ALLO has outperformed the market in the last year with a price return of +93.2% while the SPY ETF gained +22.2%. However, in the short term, ALLO had mixed performance relative to the market. It has underperformed in the last 3 months, returning -13.5% vs +5.6% return in SPY. But in the last 2 weeks, ALLO shares have fared better than the market returning +9.9% compared to SPY +6.6%.

ALLO support price is $1.98 and resistance is $2.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALLO shares will trade within this expected range on the day.